{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-010114","form_type":"8-K/A","ticker":"BDSX","cik":"0001439725","company_name":"BIODESIX INC","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.093422+00:00","generated_at":"2026-05-16T10:50:06.858285+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Biodesix prelim Q4 rev $28.8M (+41%), FY rev $88.5M (+24%), affirms positive Adj EBITDA Q4","bullets":["Estimated Q4 total revenue $28.8M (+41% YoY); full-year $88.5M (+24% YoY), exceeding raised guidance of $84-86M.","Lung Diagnostics revenue $25.2M in Q4 (+47% YoY), $79.2M FY (+22% YoY); test volumes 18,000 Q4, 62,600 FY.","Development Services revenue $3.6M Q4 (+13% YoY), $9.3M FY (+41% YoY).","Cash $19.0M as of Dec 31, 2025, up 14% from Q3, including $2.3M ATM proceeds; core cash flat.","Management affirms positive Adjusted EBITDA for Q4 2025 based on strong revenue flow-through."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-010114","json":"https://secwatch.observer/filing/0001193125-26-010114.json","markdown":"https://secwatch.observer/filing/0001193125-26-010114.md","text":"https://secwatch.observer/filing/0001193125-26-010114.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439725/000119312526010114/0001193125-26-010114-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439725/000119312526010114/bdsx-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:50:06.858285+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}